Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells

Gene Therapy volume 14, pages 366–375 (2007)Cite this article

Abstract

Dendritic cells (DC) transfected with messenger RNA (mRNA) encoding tumor-associated antigens (TAA) are able to induce potent tumor-specific T-cell responses directed to a broad spectrum of tumor-associated epitopes. The in vitro generation of DC possessing all the features crucial for the induction of type 1 immune responses, such as mature state, migratory potential and interleukin-12 (IL-12p70) production is complicated. Particularly migratory potential is inversely correlated with IL-12p70 production after maturation with prostaglandin E2 (PGE2), which is included in maturation cocktails currently used in most vaccination trials. Here, we show that transfection of PGE2 matured DC with a single mRNA strain encoding for ubiquitin followed by a TAA which was linked to IL-12 by a self-cleaving 2A sequence, produced biological active IL-12p70 and were able to present the transfected TAA up to 72 h after transfection. Furthermore, use of the anti-reverse cap analog for in vitro transcription of the IL-12 mRNA enabled constitutive IL-12p70 production for up to 5 days. These transfected mature DC migrated efficiently towards lymph node derived chemokines. DCs constitutively expressing IL-12p70, generate TAA-specific cytotoxic T cells with an high functional avidity, independent of CD4+ T-cell help.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Banchereau J, Palucka AK . Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5: 296–306.

    Article  CAS  PubMed  Google Scholar 

  2. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N . Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233–238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ingulli E, Mondino A, Khoruts A, Jenkins MK . In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med 1997; 185: 2133–2141.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Albert ML, Jegathesan M, Darnell RB . Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001; 2: 1010–1017.

    Article  CAS  PubMed  Google Scholar 

  5. Lee AW, Truong T, Bickham K, Fonteneau JF, Larsson M, Da S et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 2002; 20 (Suppl 4): A8–A22.

    Article  CAS  PubMed  Google Scholar 

  6. Scandella E, Men Y, Legler DF, Gillessen S, Prikler L, Ludewig B et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 2004; 103: 1595–1601.

    Article  CAS  PubMed  Google Scholar 

  7. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P . Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000; 164: 4507–4512.

    Article  CAS  PubMed  Google Scholar 

  8. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004; 64: 5934–5937.

    Article  CAS  PubMed  Google Scholar 

  9. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328–332.

    Article  CAS  PubMed  Google Scholar 

  10. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174: 3798–3807.

    Article  CAS  PubMed  Google Scholar 

  11. Rasmussen AB, Zocca MB, Bonefeld CM, von Essen M, Lauritsen JPH, Tomra S et al. Proteasomal targeting and minigene repetition improve cell-surface presentation of a transfected, modified melanoma tumour antigen. Scand J Immunol 2004; 59: 220–227.

    Article  CAS  PubMed  Google Scholar 

  12. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF et al. Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat Biotechnol 2004; 22: 589–594.

    Article  CAS  PubMed  Google Scholar 

  13. Donnelly ML, Luke G, Mehrotra A, Li X, Hughes LE, Gani D et al. Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal ‘skip’. J Gen Virol 2001; 82: 1013–1025.

    Article  CAS  PubMed  Google Scholar 

  14. Michiels A, Tuyaerts S, Bonehill A, Breckpot K, Heirman C, Van Meirvenne S et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Therapy 2005; 12: 772–782.

    Article  CAS  PubMed  Google Scholar 

  15. Schaft N, Dorrie J, Thumann P, Beck VE, Muller I, Schultz ES et al. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol 2005; 174: 3087–3097.

    Article  CAS  PubMed  Google Scholar 

  16. de Vries IJ, Krooshoop DJEB, Scharenborg NM, Lesterhuis WJ, Diepstra JH, van Muijen GNP et al. Effective Migration of Antigen-pulsed Dendritic Cells to Lymph Nodes in Melanoma Patients Is Determined by Their Maturation State. Cancer Res 2003; 63: 12–17.

    CAS  PubMed  Google Scholar 

  17. Gilboa E, Vieweg J . Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004; 199: 251–263.

    Article  CAS  PubMed  Google Scholar 

  18. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109: 409–417.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kyte JA, Gaudernack G . Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother [published online, 1 September 2006].

  20. Legler DF, Krause P, Scandella E, Singer E, Groettrup M . Prostaglandin E2 Is Generally Required for Human Dendritic Cell Migration and Exerts Its Effect via EP2 and EP4 Receptors. J Immunol 2006; 176: 966–973.

    Article  CAS  PubMed  Google Scholar 

  21. Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev 2003; 3: 133–146.

    CAS  Google Scholar 

  22. Schmidt CS, Mescher MF . Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J Immunol 2002; 168: 5521–5529.

    Article  CAS  PubMed  Google Scholar 

  23. MacGregor JN, Li Q, Chang AE, Braun TM, Hughes DPM, McDonagh KT . Ex vivo culture with interleukin (IL)-12 improves CD8+ T-cell adoptive immunotherapy for murine leukemia independ. Cancer Res 2006; 66: 4913–4921.

    Article  CAS  PubMed  Google Scholar 

  24. Vujanovic L, Ranieri E, Gambotto A, Olson WC, Kirkwood JM, Storkus WJ . IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro. Cancer Gene Ther 2006; 13: 798–805.

    Article  CAS  PubMed  Google Scholar 

  25. Bontkes HJ, Ruizendaal JJ, Kramer D, Meijer CJ, Schreurs MW, Hooijberg E . Interleukin-12 increases proliferation and Interferon- production but not cytolytic activity of human antigen specific effector memory Cytotoxic T-lymphocytes; power of the effect depends on the functional avidity of the T-cell and antigen concentration. Hum Immunol 2006; 66: 1137–1145.

    Article  Google Scholar 

  26. Scholten KB, Kramer D, Kueter EW, Graf M, Schoedl T, Meijer CJ et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 2006; 119: 135–145.

    Article  CAS  PubMed  Google Scholar 

  27. Su Z, Vieweg J, Weizer AZ, Dahm P, Yancey D, Turaga V et al. Enhanced induction of telomerase-specific cd4+ t cells using dendritic cells transfected with rna encoding a chimeric gene product. Cancer Res 2002; 62: 5041–5048.

    CAS  PubMed  Google Scholar 

  28. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004; 172: 6649–6657.

    Article  CAS  PubMed  Google Scholar 

  29. Mockey M, Goncalves C, Dupuy FP, Lemoine FM, Pichon C, Midoux P . mRNA transfection of dendritic cells: Synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem Biophys Res Commun 2006; 340: 1062–1068.

    Article  CAS  PubMed  Google Scholar 

  30. Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M et al. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003; 171: 2251–2261.

    Article  CAS  PubMed  Google Scholar 

  31. Hamann D, Roos MT, van Lier RAW . Faces and phases of human CD8+ T-cell development. Immunol Today 1999; 20: 177–180.

    Article  CAS  PubMed  Google Scholar 

  32. Hiura T, Kagamu H, Miura S, Ishida A, Tanaka H, Tanaka J et al. Both regulatory t cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol 2005; 175: 5058–5066.

    Article  CAS  PubMed  Google Scholar 

  33. Dannull J, Nair S, Su Z, Boczkowski D, DeBeck C, Yang B et al. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 2005; 105: 3206–3213.

    Article  CAS  PubMed  Google Scholar 

  34. Grunebach F, Kayser K, Weck MM, Muller MR, Appel S, Brossart P . Cotransfection of dendritic cells with RNA coding for HER-2//neu and 4–1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes. Cancer Gene Ther 2005; 12: 749–756.

    Article  PubMed  Google Scholar 

  35. Michiels A, Breckpot K, Corthals J, Tuyaerts S, Bonehill A, Heirman C et al. Induction of antigen-specific CD8(+) cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Therapy 2006; 13: 1027–1036.

    Article  CAS  PubMed  Google Scholar 

  36. Loskog A, Ninalga C, Totterman TH . Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors. Cancer Immunol Immunother 2006; 55: 588–597.

    Article  PubMed  Google Scholar 

  37. Hooijberg E, Ruizendaal JJ, Snijders PJ, Kueter EW, Walboomers JM, Spits H . Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. J Immunol 2000; 165: 4239–4245.

    Article  CAS  PubMed  Google Scholar 

  38. Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 1995; 154: 116–127.

    CAS  PubMed  Google Scholar 

  39. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998; 160: 1750–1758.

    CAS  PubMed  Google Scholar 

  40. Van Tendeloo VFI, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001; 98: 49–56.

    Article  CAS  PubMed  Google Scholar 

  41. Cunningham PR, Ofengand J . Use of inorganic pyrophosphatase to improve the yield of in vitro transcription reactions catalyzed by T7 RNA polymerase. Biotechniques 1990; 9: 713–714.

    CAS  PubMed  Google Scholar 

  42. Bontkes HJ, de Gruijl TD, Schuurhuis GJ, Scheper RJ, Meijer CJ, Hooijberg E . Expansion of dendritic cell precursors from human CD34(+) progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome. J Leukoc Biol 2002; 72: 321–329.

    CAS  PubMed  Google Scholar 

  43. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196: 137–151.

    Article  CAS  PubMed  Google Scholar 

  44. Snijders A, Hilkens CM, Van der Pouw Kraan TC, Engel M, Aarden LA, Kapsenberg ML . Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J Immunol 1996; 156: 1207–1212.

    CAS  PubMed  Google Scholar 

  45. Schreurs MW, Scholten KB, Kueter EW, Ruizendaal JJ, Meijer CJ, Hooijberg E . In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J Immunol 2003; 171: 2912–2921.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank A Stam for technical assistance, and the Maurits and Anna de Kock Foundation for financial support in the purchase of an HPLC. We thank Dr ML Kapsenberg for providing IL-12 antibodies and Dr S Hallez for providing the ubiquitin open-reading frame. We are grateful to Drs KJB Scholten and Dr MWJ Schreurs for fruitful discussions. This work was financially supported by Dutch Cancer Society (KWF) Grant VU2002-2627. VFIVT is a postdoctoral fellow of the fund for Scientific Research-Flanders (FWO-Vlaanderen).

Author information

Authors and Affiliations

  1. Department of Pathology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

    H J Bontkes, D Kramer, J J Ruizendaal, E W M Kueter, C J L M Meijer & E Hooijberg

  2. Laboratory of Experimental Hematology, Faculty of Medicine, University of Antwerp, Antwerp University Hospital, Antwerp, Belgium

    V F I van Tendeloo

Authors
  1. H J Bontkes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Kramer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J J Ruizendaal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E W M Kueter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V F I van Tendeloo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C J L M Meijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Hooijberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H J Bontkes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bontkes, H., Kramer, D., Ruizendaal, J. et al. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther 14, 366–375 (2007). https://doi.org/10.1038/sj.gt.3302874

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302874

Keywords

This article is cited by

Search

Advanced search

Quick links